Method for reducing toxicity of chrysophanol and application
By combining rhubarb phenol with Gastroentin, it promotes its metabolism and inhibits the expression of related toxic proteins, the cytotoxicity problem of rhubarb phenol is solved, and its toxicity reduction and cell protection effect is achieved.
Patent Information
- Application Number
- CN202411100366.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-09
- Publication Date
- 2024-11-26
AI Technical Summary
Rhumphenol has potential cytotoxicity and hepatotoxicity, which limits its use in clinical applications. Currently, there are few studies on its toxic mechanism and attenuation methods.
By combining rhubarb with Gastrodiatin, Gastrodiatin can promote the metabolism of rhubarb by human liver microsomes and CYP1A2 enzymes, inhibit the expression of proteins Bax and Caspase-3, prolong the S and G2 phases of cells, thereby weakening rhubarb Cytotoxicity.
It effectively reduces the toxic effect of rhubarb phenol on hepatocytes, reduces its apoptosis and morphological changes on hepatocytes, improves the cell cycle, and provides a theoretical basis for safer use of rhubarb phenol.
Smart Images

Figure CN119015296A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and particularly relates to a method for reducing the toxicity of chrysophanol and an application thereof. Background Art
[0002] Pinellia is the dried tuber of Pinellia ternata of the Araceae family, and it is one of the ingredients of many Chinese patent medicines. The chemical components of Pinellia ternata include volatile oils, fats, starch, sterols, organic acids, anthraquinones, amino acids and inorganic elements, as well as alkaloids and irritants. Studies have shown that chrysophanol exists in Pinellia ternata as a free aglycone, which is a high-content anthraquinone substance and mainly plays a lipid-lowering role. Chrysophanol is one of the active ingredients in Pinellia ternata that has a lipid-lowering effect. It is also called 1,8-dihydroxy-3-methylanthraquinone, and its molecular formula is C 15 H 10 O4, with a relative molecular weight of 254.23, contains carbonyl, hydroxyl and anthraquinone tricyclic aromatic structures. The pharmacological effects of chrysophanol mainly include antioxidant, anti-tumor, anti-inflammatory, antibacterial, hypolipidemic and hemostatic effects. It is often used in clinical practice to treat diseases such as cerebral ischemia-reperfusion and Alzheimer's disease. In recent years, its neuroprotective and lipid-regulating effects have been widely studied by scholars. However, there are more and more reports on the toxic and side effects of natural anthraquinone compounds. As a natural anthraquinone derivative, chrysophanol has a wide range of pharmacological activities, but also has potential cytotoxicity and other side effects, especially when used in high doses and for a long time.
[0003] It has been found through research that chrysophanol has certain hepatotoxicity, which brings great harm to the body, affects its drug metabolizing enzymes and thus affects its efficacy, thus limiting the clinical application of the drug. Pharmacokinetic studies have shown that chrysophanol combined with other drugs can reduce cytotoxicity and enhance efficacy. For example, the combination of rhubarb and aconite can slow down the absorption and elimination rate of chrysophanol in rhubarb, playing a role in reducing toxicity and increasing efficacy. However, there are few studies on the toxicity mechanism of chrysophanol and its detoxification method. Therefore, the present invention studies the specific toxicity mechanism and detoxification method of chrysophanol. Summary of the invention
[0004] The purpose of the present invention is to provide a method for reducing the toxicity of chrysophanol and its application. It is found that gastrodin can promote the metabolism of chrysophanol by human liver microsomes and CYP1A2 enzyme, and can also inhibit the expression of proteins Bax and Caspase-3 to weaken the cytotoxicity of chrysophanol. At the same time, it can prolong the S and G2 phases of LO2 cells, thereby improving cell apoptosis, providing a theoretical basis for further utilizing chrysophanol.
[0005] The objective of the present invention is achieved through the following technical solutions:
[0006] The invention provides a method for reducing the toxicity of chrysophanol, which comprises combining chrysophanol with gastrodin.
[0007] Furthermore, the concentration ratio of chrysophanol to gastrodin is 1:1-1:40.
[0008] The invention also provides a medicine capable of reducing the toxicity of chrysophanol, wherein the medicine comprises gastrodin.
[0009] The present invention also provides an application of gastrodin in the preparation of a drug for reducing the toxicity of chrysophanol. The reducing the toxicity of chrysophanol includes promoting the metabolism of chrysophanol by human liver microsomes and reducing the influence of chrysophanol on the activity of liver cells.
[0010] Furthermore, the reducing effect of chrysophanol on hepatocyte activity includes inhibiting the effect of chrysophanol on hepatocyte morphology, reducing hepatocyte apoptosis caused by chrysophanol, regulating hepatocyte cycle and regulating the expression of apoptosis-related proteins in normal human cells.
[0011] Furthermore, the regulation of the expression of proteins related to apoptosis in normal human cells includes down-regulating the expression of proteins Bax and Caspase-3 caused by chrysophanol.
[0012] Furthermore, the regulating the hepatocyte cell cycle includes prolonging the S and G2 phases of the hepatocytes.
[0013] The beneficial effects of the present invention are:
[0014] 1. The present invention simulates the metabolic process of chrysophanol by in vitro metabolism method. The in vitro metabolites of chrysophanol in normal human liver cells, human liver microsomes, mouse liver microsomes and intestinal flora are identified by HPLC-TOF-MS / MS technology, and the liver is found to be the main metabolic site of chrysophanol.
[0015] 2. The present invention found in the research process that in human liver microsomes, CYP1A2 enzyme is the main metabolic enzyme of chrysophanol, and its metabolic rate is 31.25%. After metabolism, M1 type hydroxylated metabolites: aloe-emodin can be generated. It is revealed that the main metabolic mechanism of chrysophanol is related to the hydroxylation reaction of CYP1A2. And after gastrodin and hesperidin were respectively matched with chrysophanol, it was found that gastrodin promoted the metabolism of chrysophanol by human liver microsomes and CYP1A2 enzyme, and hesperidin inhibited the metabolism of chrysophanol by human liver microsomes.
[0016] 3. The present invention has found that the cytotoxicity of chrysophanol is related to proteins Bax and Caspase-3, and gastrodin can reduce the cytotoxicity of chrysophanol by inhibiting the expression of these two proteins. After chrysophanol and gastrodin are combined, the S and G2 phases of LO2 cells are prolonged, thereby improving cell apoptosis, indicating that gastrodin can improve the cell cycle arrest caused by chrysophanol and reduce the effect of chrysophanol on the morphology of stem cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 The EIC graphs of chrysophanol metabolites in hepatocytes; (A) is the extracted ion current graph of 80 μg / mL chrysophanol metabolites (269.04 Da); (B) is the extracted ion current graph of 25 μg / mL chrysophanol metabolites (269.04 Da); (C) is the extracted ion current graph of 10 μg / mL chrysophanol metabolites (269.04 Da);
[0018] Figure 2 Extracted ion chromatograms of samples before (A) and after (B) incubation with chrysophanol in human liver microsomes;
[0019] Figure 3 The extracted ion currents of four metabolites of chrysophanol in human liver microsomes, among which (A) is the extracted ion current of M1 type (m / z=269.04) metabolites; (B) is the extracted ion current of M2 type (m / z=285.04) metabolites; (C) is the extracted ion current of M3 type (m / z-283.02) metabolites; (D) is the extracted ion current of M4 type (m / z=239.0) metabolites;
[0020] Figure 4 Extracted ion chromatograms of samples before (A) and after (B) incubation with chrysophanol in rat liver microsomes;
[0021] Figure 5 The extracted ion currents of four metabolites of chrysophanol in rat liver microsomes, among which (A) is the extracted ion current of M1 type (m / z=269.04) metabolites; (B) is the extracted ion current of M2 type (m / =285.04) metabolites; (C) is the extracted ion current of M3 type (m / z=283.02) metabolites; (D) is the extracted ion current of M4 type (m / z=239.0) metabolites;
[0022] Figure 6 This is the average blood concentration-time curve after administration of chrysophanol;
[0023] Figure 7 The ion extraction chromatograms of chrysophanol (A, B) and metabolite ion extraction chromatograms (C, D) before and after incubation with CYP1A2 of chrysophanol;
[0024] Figure 8 The ion extraction chromatograms of metabolites of chrysophanol before incubation with five iso-recombinant P450 enzymes, including (A) CYPIA2, (B) CYP3A4, (C) CYP2C9, (D) CYP2C19, (E) CYP2D6, and (F) CYP2EI;
[0025] Fig. 9 EIC diagram of chrysophanol before (A) and after (B) metabolism in human liver microsomes;
[0026] Fig.10 EIC diagram of chrysophanol combined with gastrodin before (A) and after (B) metabolism in human liver microsomes;
[0027] Fig.11 EIC diagram of chrysophanol before (A) and after (B) metabolism by CYPIA2;
[0028] Fig.12 EIC diagram of chrysophanol combined with gastrodin before (A) and after (B) metabolism by CYP1A2;
[0029] Fig.13 EIC diagram of chrysophanol before (A) and after (B) metabolism in human liver microsomes;
[0030] Fig.14 EIC diagram of chrysophanol combined with hesperidin before (A) and after (B) metabolism in human liver microsomes;
[0031] Fig.15 The results of cytotoxicity of chrysophanol are shown in Figure 1, where a. the effect of different concentrations on cytotoxicity of chrysophanol, b. the activity of LO2 cells incubated with chrysophanol at different concentrations for 24 hours, c. the activity of LO2 cells incubated with chrysophanol at different concentrations for 48 hours, d. the activity of LO2 cells incubated with chrysophanol at different concentrations for 72 hours (compared with the control group, *p<0.05, **p<0.01, ***p<0.001), e. the effect of concentration and incubation time of chrysophanol on cytotoxicity (*p<0.05, **p<0.01, ***p<0.001);
[0032] Fig.16 The diagrams are the effects of gastrodin and chrysophanol on the activity of LO2 cells before and after the combination, including: a. The effect of different concentrations of gastrodin on the activity of LO2 cells, b. The effect of 25μg / mL chrysophanol combined with different concentrations of gastrodin on the activity of LO2 cells, c. The effect of 80μg / mL chrysophanol combined with different concentrations of gastrodin on the activity of LO2 cells (compared with the control group, *p<0.05, **p<0.01, ***p<0.001);
[0033] Fig.17 The effect of the combination of chrysophanol and gastrodin on the morphology of LO2 cells (24h);
[0034] Fig.18 To study the effect of chrysophanol combined with gastrodin on apoptosis of LO2 cells;
[0035] Fig.19 To study the effect of gastrodin combined with chrysophanol on the cell cycle of LO2 cells;
[0036] Fig. 20The effect of gastrodin and chrysophanol on apoptosis (a) and cell cycle (b) of LO2 cells before and after their combination (compared with the control group, *p<0.05, **p<0.01, ***p<0.001; compared with the 40μg / mL chrysophanol group, ##p<0.01);
[0037] Fig.21 The effects of chrysophanol combined with gastrodin on apoptosis-related proteins; (A) is the effect of chrysophanol combined with gastrodin on BAX; (B) is the effect of chrysophanol combined with gastrodin on chrysophanol spase-3 (compared with the control group, *p<0.05, **p<0.01; compared with 40μg / mL chrysophanol group, #p<0.05, ##p<0.01). DETAILED DESCRIPTION
[0038] The present invention is described in more detail below in conjunction with the following embodiments. It should be understood that the implementation of the present invention is not limited to the following embodiments, and any modifications and / or changes made to the present invention will fall within the scope of protection of the present invention.
[0039] Wherein, the specific reagents used in the following examples are as follows:
[0040] Chrysophanol (purchased from Shanghai Yuanye Biotechnology Co., Ltd.), gastrodin (purchased from Shanghai Yuanye Biotechnology Co., Ltd.), hesperidin (purchased from Shanghai Yuanye Biotechnology Co., Ltd.), trypsin cell digestion solution (purchased from Biosharp (China)), Sijiqing fetal bovine serum (purchased from Zhejiang Tianhang Biotechnology Co., Ltd.), CCK-8 kit (purchased from Dalian Meilun Biotechnology Co., Ltd.), GAM broth culture medium (purchased from Shanghai Curie Biotechnology Co., Ltd.), anticoagulant centrifuge tube (purchased from Jiangsu Kangjian Medical Supplies Co., Ltd.), Tween-20 (purchased from Shanghai Shenggong Biotechnology Co., Ltd.), anaerobic gas generation bag (purchased from Qingdao Haibo Biotechnology Co., Ltd.), anaerobic culture bag (purchased from Qingdao Haibo Biotechnology Co., Ltd.) Company), C18 chromatographic column (purchased from Waters (USA)), HLM human liver microsomes (purchased from Beijing Huizhiheyuan Biotechnology Co., Ltd.), HS9 mouse liver microsomes (purchased from Beijing Huizhiheyuan Biotechnology Co., Ltd.), NADPH coenzyme kit (purchased from Beijing Huizhiheyuan Biotechnology Co., Ltd.), dialysis bag (purchased from Qingdao Haibo Biotechnology Co., Ltd.), anaerobic culture medium (purchased from Qingdao Haibo Biotechnology Co., Ltd.), recombinant P450 enzyme (purchased from Beijing Huizhiheyuan Biotechnology Co., Ltd.), PBS buffer (purchased from Hyclone), anhydrous ethanol (purchased from Sinopharm Chemical Reagent Co., Ltd.), methanol (purchased from Sinopharm Chemical Reagent Co., Ltd.), DMEM high glucose medium (purchased from High Glucose), Penicillin-Sterptomycin (purchased from Hyclone (USA)), PageRuler prestained protein (purchased from Marker Thermo Fisher (USA)), RIPA lysis buffer (purchased from Shanghai Biotech Co., Ltd. (China)), skim milk powder (purchased from sangon), TBST (dry powder) (purchased from coolaber), high-sensitive ECL chemiluminescence detection kit (purchased from Fude Biotechnology), SDS-PAGE protein loading buffer (purchased from Shanghai Biotech Co., Ltd.), primary antibody diluent (purchased from Shanghai Biotech Co., Ltd.), cell-grade dimethyl sulfoxide (purchased from MACKLIN), 0.2μM PVDF membrane (purchased from Shanghai Biotech Co., Ltd.), PMSF (purchased from Thermo Fisher Scientific), BCA protein quantification kit Thermo Fisher Scientific), 30% polyacrylamide (purchased from Sangon Biotech (Shanghai) Co., Ltd.), PI / AnnexinV-FITC kit (purchased from MultiSciences).
[0041] Example 1 Study on the metabolism of chrysophanol
[0042] 1. Sample Solution Preparation
[0043] (1) Chrysophanol standard solution (for in vitro incubation experiment): Accurately weigh 1 mg of chrysophanol standard solid powder, dissolve it in 1 mL of methanol, vortex for 3 min, and ultrasonically dissolve it for 5 min to prepare a standard stock solution with a mass concentration of 1 mg / mL. Use methanol to dilute the prepared stock solution to a chrysophanol sample solution with a concentration of 500 μg / mL for later use.
[0044] (2) Gastrodin standard solution (for in vitro incubation experiment): Accurately weigh 2 mg of solid powder of gastrodin standard, dissolve it in 2 mL of PBS, vortex for 2 min, and prepare a standard stock solution with a mass concentration of 2 mg / mL. Use PBS to dilute the stock solution to a gastrodin sample solution with a mass concentration of 500 μg / mL for later use.
[0045] (3) Preparation and sterilization of anaerobic culture medium: Accurately weigh 59 g of GAM (GifuAnaerobicMedium) broth culture medium, place it in a 2000 mL beaker, add an appropriate amount of distilled water, stir and dissolve in an 80°C water bath, and add distilled water to 1000 mL. Transfer the culture medium into a conical flask, seal it with gauze and newspaper, and sterilize it together with 5 150 mL sealed conical flasks (for dispensing culture medium) under high pressure (121°C, 0.120 MPa) for 20 min, transfer it to a clean bench and cool it to room temperature for use.
[0046] (4) Collection of fecal samples and preparation of intestinal flora incubation solution: Fresh fecal samples from 20 healthy mice were collected into sterile EP tubes, quickly transferred into anaerobic culture bags, and placed on a clean bench. In the clean bench, each fecal sample was quickly weighed and divided into other sterile EP tubes, and mixed with sterile saline at a ratio of 1g:4mL (W / V) to make a suspension, vortexed for 3min, centrifuged at 500rpm for 5min, and the supernatant was taken as intestinal flora incubation solution for later use. The treated intestinal flora incubation solution was diluted to 1 / 2 and 1 / 4, and together with the original incubation solution, it was regarded as low, medium, and high concentration intestinal flora incubation solution.
[0047] (5) Chrysophanol reference solution (for in vivo metabolism experiments): Accurately weigh 5 mg of chrysophanol reference solution and place it in a 50-mL volumetric flask. Add an appropriate amount of methanol and sonicate until it is completely dissolved. Then, make up to the mark and shake evenly to prepare a 100 μg / mL reference solution. Store at 4°C in the dark.
[0048] (6) Chrysophanol test solution (for in vivo metabolism experiments): Use a 100-μL pipette to precisely pipette 100 μL of blank plasma into a 1.5-mL conical centrifuge tube. Add different concentrations of chrysophanol reference solution to prepare samples with concentrations of 0.5, 2, 5, 10, 20, 40, and 80 μg / mL. Prepare samples immediately before use.
[0049] 2. Experimental Plan
[0050] 2.1 In vitro experimental protocol
[0051] (1) Hepatocyte metabolism: LO2 cells were revived one week before the experiment and cultured in DMEM containing 10% fetal bovine serum at 37°C, 5% CO2 and saturated humidity. Cells in the logarithmic growth phase were used for the experiment. The low, medium and high concentrations of chrysophanol were 10 μg / mL, 25 μg / mL and 80 μg / mL, respectively, and incubated overnight for 24 h.
[0052] The cell density was adjusted to 7 × 10 5 10 mL / bottle was inoculated into the culture bottle. After 24 hours of culture, three concentrations of chrysophanol solution and NADPH were added respectively (NADPH was diluted with serum-free DMEM medium and placed in a 37°C incubator for preheating, and the final concentration in the system was 1 mM). The experimental groups were as follows:
[0053] Blank group: LO2 cells + DMEM (5% FBS);
[0054] Control group: 80 μg / mL chrysophanol solution + DMEM (5% FBS);
[0055] Low-concentration experimental group: LO2 cells + 10 μg / mL chrysophanol solution + DMEM (5% FBS); medium-concentration experimental group: LO2 cells + 25 μg / mL chrysophanol solution + DMEM (5% FBS); high-concentration experimental group: LO2 cells + 80 μg / mL chrysophanol solution + DMEM (5% FBS). After incubation for 24 hours at 37°C and 5% CO2, the culture fluid was collected for sample pretreatment.
[0056] (2) Liver microsomal metabolism: The total volume of the incubation system was 200 μL, and the system contained 40 μL of drug, 20 μL of human liver microsomes or mouse liver microsomes (HLM / HS9) with a final concentration of 1.0 mg / mL, 40 μL of NADPH, and 100 μL of phosphate buffer (PBS, 0.1 M, pH = 7.4). The NADPH system contained 10 μL of solution A (β-nicotinamide adenine dinucleotide phosphate sodium salt, magnesium chloride aqueous solution, and glucose-6-phosphate) and 2 μL of solution B (sodium citrate solution and glucose-6-phosphate dehydrogenase).
[0057] Experimental steps: HLM / HS9 was mixed with 500 μg / mL chrysophanol solution, pre-incubated at 37°C for 5 minutes, NADPH was added to start the reaction, and the reaction was continued at 37°C for 45 minutes. After the incubation, a certain amount of ice methanol was added to terminate the reaction. A control group without NADPH was set up in parallel. The organic solvent in the drug should not exceed 1% of the total volume of the incubation system.
[0058] Choose the best method for protein removal from the following treatments:
[0059] ① Add 400 μL of ice methanol to inactivate, vortex to mix, and centrifuge at 10000 rpm at 4°C for 10 min;
[0060] ② Add 500 μL of ice methanol to inactivate, vortex to mix, and centrifuge at 10000 rpm at 4°C for 10 min;
[0061] ③ Add 600 μL of ice methanol to inactivate, vortex to mix, and centrifuge at 10000 rpm at 4°C for 10 min;
[0062] ④ Add 400 μL of ice methanol to inactivate, vortex to mix, and centrifuge at 10000 rpm at 4°C for 20 min;
[0063] ⑤ Add 500 μL of ice methanol to inactivate, vortex to mix, and centrifuge at 10000 rpm at 4°C for 20 min;
[0064] ⑥ Add 600 μL of ice methanol to inactivate, vortex mix, and centrifuge at 4℃10000rpm for 20 min. This experiment selected method ⑥ as the protein precipitation method, that is, add 600 μL of ice methanol to inactivate, vortex mix, and centrifuge at 4℃10000rpm for 20 min.
[0065] After precipitation, the supernatant was aspirated and passed through the membrane, and then an equal volume of methanol was added, vortexed to mix, and centrifuged at 4°C and 10,000 rpm for 10 minutes. Observe whether there is precipitation to verify whether the protein is completely removed.
[0066] (3) Intestinal flora metabolism: 10 mL of anaerobic culture medium was mixed with 1 mL of intestinal bacteria incubation solution of different concentrations at 37°C, placed in an anaerobic culture bag, and an anaerobic gas production bag was added. After 24 hours of overnight culture, 100 μL of chrysophanol solution (500 μg / mL) was added as the incubation group, and the incubation was continued for 24 hours under anaerobic conditions. Three samples were prepared in parallel. An intestinal bacteria control group (100 μL of methanol was used instead of chrysophanol, and the rest was the same as the incubation group) and a blank group without intestinal bacteria (10 mL of anaerobic culture solution) were also set up.
[0067] The metabolic rate of chrysophanol was calculated according to the following formula:
[0068] Chrysophanol metabolism rate % = (control group peak area - metabolite group peak area) / control group peak area × 100%
[0069] 2.2 In vivo metabolic scheme
[0070] (1) Experimental animals
[0071] C57BL / 6 mice, male (20±2g), clean grade, were purchased from the Animal Experiment Center of Hangzhou Normal University. The mice were housed in a clean animal room (temperature 23±2°C, humidity 60±5%, 24h day and night alternation), and were fed with distilled water and standard feed every day.
[0072] (2) Experimental groups
[0073] This animal experiment was a single oral administration, and the mice were divided into 2 groups. Blank group: 6 healthy mice, regular diet, free drinking water, blood was collected after one week of environmental adaptation; normal administration group: 6 healthy mice, regular diet, free drinking water, administration after one week of environmental adaptation, fasting for 12 hours before administration, and oral administration of chrysophanol solution 20 mg / kg [solvent: DMF-Tween-80-normal saline (1:1:8)] after weighing.
[0074] (3) Plasma sample collection
[0075] Before administration, 200 μL of blank blood was collected, and 200 μL of blood was collected from the orbital vein at 0.5, 1, 3, 6, and 12 hours after intragastric administration. The blood was placed in a centrifuge tube containing 1% sodium heparin saline, centrifuged at 8000 rpm for 10 minutes, and the supernatant was stored in a -80°C refrigerator.
[0076] 3. Detection Methods
[0077] 3.1 Sample pretreatment
[0078] (1) Hepatocyte metabolism samples: The concentrated culture medium was dialyzed using a dialysis bag with a relative molecular weight of 1000. The dialysate was concentrated and lyophilized to obtain metabolites with a relative molecular weight below 1000. The metabolites were reconstituted with 100 μL of 80% methanol and centrifuged at 12,000 rpm for 10 min. 50 μL of the supernatant was taken for sample analysis.
[0079] (2) Liver microsomal metabolism samples: Pre-treat according to the protein precipitation conditions in step 2.1 (1), filter the supernatant with a 0.22 μm organic filter membrane, and aspirate 200 μL of the filtrate into an inner liner tube for LC-TOF-MS analysis.
[0080] (3) Intestinal flora metabolism samples: Collect the culture medium after incubation and place it in a sterilized EP tube. Centrifuge at 800 rpm for 5 min and take the supernatant. Add 3 times the volume of ice methanol to the supernatant of each group, vortex mix for 3 min, centrifuge at 10,000 rpm at 4°C for 10 min, and take the supernatant. Dry under nitrogen flow at 37°C, and dissolve the residue in 200 μL 80% methanol. Centrifuge at 10,000 rpm at 4°C for 10 min, take 100 μL of the supernatant, and use LC-TOF-MS / MS to qualitatively analyze its metabolites.
[0081] (4) Plasma samples: Take 100 μL of mouse plasma, add 1.5 mL of methanol, vortex for 3 min to mix, centrifuge at 12000 rpm at 4°C for 10 min, and take the supernatant. Dry at 37°C under nitrogen flow, reconstitute with 100 μL of 80% methanol, centrifuge at 12000 rpm at 4°C for 10 min, and take 50 μL of the supernatant for analysis.
[0082] 3.2 Test conditions
[0083] (1) LC-TOF-MS detection conditions for chrysophanol: The chromatographic column was a C18 column (4.6×250 mm, 5 μm), the mobile phase A was ultrapure water, the mobile phase B was methanol, and gradient elution was performed. The elution time was 17 min, and the specific elution program was shown in Table 1. The column temperature was set to 30°C, the injection volume was 10 μL, and the volume flow rate was 0.5 mL / min. Negative ion mode was used for detection. The ion source voltage was -3000 V, the temperature was 120°C, the elution solvent gas temperature was 350°C, the spray gas was high-purity nitrogen (N2), the collision gas was high-purity argon, the backflush gas flow rate was 80 L / h, the elution solvent gas flow rate was 800 L / h, the mass spectrometry scanning range was 50-1200 Da, and the real-time calibration standard substance m / z=557.2771+ (leucine enkephalin).
[0084] Table 1 LC-TOF-MS elution program
[0085]
[0086]
[0087] (2) HPLC detection conditions for chrysophanol: A C18 column (4.6×150 mm, 5 μM) was used, with ultrapure water as phase A and methanol as phase B for gradient elution. The elution time was 50 min, and the elution program was as shown in Table 2. The column temperature was set at 30°C, the flow rate was 1 mL / min, the injection volume was 10 μL, and the absorption wavelength was 287 nm.
[0088] Table 2 HPLC elution program
[0089] Time(min) A(%) B(%) 0 95 5 10 80 20 18 70 30 22 20 80 25 5 95 35 0 100 50 0 100
[0090] 4 Experimental results
[0091] 4.1 In vitro metabolic results
[0092] 4.1.1 Identification of hepatic metabolites of chrysophanol
[0093] The results showed that chrysophanol has a metabolic reaction in hepatocytes. The calculated metabolic rate of chrysophanol was 54.62%. The experiment identified a hydroxylated metabolite M1 in the chrysophanol metabolome (specifically Figure 1 The mass-to-charge ratio is 269.04Da, the retention time is 11.76min, and the molecular formula of the product is C 15 H 10 O5.
[0094] 4.1.2 Identification of in vitro metabolites of chrysophanol in liver microsomes
[0095] The prototype of chrysophanol (specifically, Figure 2 ) and 4 metabolites (specifically Figure 3 In addition, the prototype of chrysophanol was also found in the rat liver microsome (HS9) incubation system (as shown in Figure 4 as shown) and the same four metabolites as in the HLM system (specifically as Figure 5 The peak area of chrysophanol in the HLM incubation group decreased by 6328 compared with the control group, and the peak area of chrysophanol in the HS9 incubation group decreased by 1266 compared with the control group. The calculated metabolic rates of chrysophanol in HLM and HS9 were 49.79% and 40.68%, respectively. Table 3 lists the mass spectrometry information of the metabolites of chrysophanol in the HLM and HS9 systems. The mass-to-charge ratios of the four metabolites were 269.04Da, 285.03Da, 283.04Da and 239.03Da, and the molecular formula was C 15 H 10 O5, C 15 H 10 O6, C 14 H7O4、C 15 H8O6. According to its secondary mass spectrum analysis, the metabolic pathway of chrysophanol is hydroxylation, carboxylation and demethylation.
[0096] The peak areas of M1-4 metabolites in the HLM system were 3370, 802, 2126 and 441, respectively, and those in the HS9 system were 3501, 541, 913 and 201, respectively. The relative contents of the four metabolites were considered according to the peak area relative quantitative method. The results showed that in both metabolic enzyme systems, the metabolite with the highest relative content was the M1 metabolite aloe-emodin.
[0097] Table 3 Metabolite information
[0098]
[0099] The established HPLC method was used to determine the blood concentration of chrysophanol in mice, and a blood concentration-time curve was drawn (specifically, Figure 6 As shown). The results showed that the pharmacokinetic parameters of chrysophanol were obtained by non-compartmental analysis using DAS2.0 software (prepared by the Chinese Pharmacological Society): half-life T1 / 2, peak blood concentration Cmax, 12h area under the curve (Area Under the Curve, AUC), total area under the curve AUC0~t and mean retention time (Mean Retention Time, MRT) were 7.646±0.282h, 2.944±0.147μg / mL, 2.186±0.853μg / mL, 1.484±0.311μg / mL and 10.368±0.417h, respectively. According to the standard curve of the chrysophanol test solution, the mean blood concentration of 12h was calculated to be 0.64±0.03μg / mL. Compared with the peak blood concentration at 1 hour, it decreased by about 2.31 μg / mL, indicating that chrysophanol eliminated 78.46% of the peak blood concentration after 11 hours.
[0100] In summary, this embodiment simulated the metabolic process of chrysophanol by in vitro metabolism method. And HPLC-TOF-MS / MS technology was used to identify the in vitro metabolites of chrysophanol in normal human liver cells, human liver microsomes, mouse liver microsomes and intestinal flora. The results showed that chrysophanol underwent metabolic reactions in liver cells, human liver microsomes, mouse liver microsomes and intestinal flora. The calculated metabolic rates of chrysophanol were 54.62%, 49.79%, 40.68% and 45.42%, respectively. This indicates that chrysophanol is absorbed into the blood after liver metabolism and intestinal metabolism in the body, and it is speculated that the liver is its main metabolic site. Among them, one identical hydroxylated metabolite was identified in both liver cells and intestinal flora: aloe-emodin. A total of four chrysophanol metabolites M1-4 (C 15 H 10 O5, C 15 H 10 O6, C 14 H7O4、C 15H8O6). It was found that the metabolites of chrysophanol detected in the HLM sample could also be detected in the HS9 sample, indicating that the metabolic pathways of chrysophanol are similar in the human body and rats. It was further confirmed that the liver is the main metabolic site of chrysophanol. In this example, after structural identification of the metabolites of chrysophanol, it was speculated that the possible metabolic pathways in the body are hydroxylation, carboxylation and demethylation. By comparing the relative peak areas of the four metabolites, it was speculated that the reduced metabolite M1 (aloe-emodin) is the most important metabolite of chrysophanol. A large number of hydroxylated metabolites of chrysophanol were identified in the intestinal flora, indicating that the intestinal flora also has a metabolic effect on chrysophanol.
[0101] The experiments in this section found that chrysophanol was metabolized into aloe-emodin in hepatocytes, human liver microsomes, mouse liver microsomes and intestinal flora, and its relative content was the highest, indicating that aloe-emodin may be the main effector substance of chrysophanol.
[0102] Pharmacokinetic parameters showed that after oral administration of chrysophanol, the peak time Tmax in mice was 1h, and the peak value was 2.944±0.147μg / mL, indicating that chrysophanol was absorbed quickly in the body. The half-life was 7.646±0.282h, and the average residence time in the body was 10.368±0.417h. 11h after the peak, the elimination rate of the drug in the body was 78.64%, and 2.304μg / mL was eliminated, indicating that chrysophanol was eliminated slowly in the body.
[0103] Example 2 Effects of Gastrodin and Hesperidin on Chrysophanol Metabolism
[0104] 1. Experimental Protocol
[0105] 1.1 Screening of key metabolic enzymes of chrysophanol
[0106] Chrysophanol was co-incubated with 6 recombinant CYP enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4) in vitro. The incubation system included 40 μL of chrysophanol, 20 μL of recombinant human P450 enzyme (protein concentration 1.0 mg / mL) and 100 μL of PBS. After incubation for 5 minutes, 40 μL of NADPH (final volume: 200 μL) was added and incubated again for 3 hours. 600 μL of ice methanol was added to inactivate the P450 enzyme, and the reaction was terminated. The supernatant was centrifuged, dried with nitrogen, and then re-dissolved with 80% methanol for testing.
[0107] 1.2 Incubation scheme of liver microsomes with gastrodin and chrysophanol
[0108] The incubation system was the same as the in vitro metabolic incubation system of liver microsomes in Example 1. The experimental groups were as follows:
[0109] (1) Gastrodin control group: 40 μL of gastrodin (500 μg / mL), 20 μL of HLM and 100 μL of PBS were mixed, pre-incubated for 5 min, and 20 μL of PBS was added. Incubation was continued for 45 min, and 600 μL of ice methanol was added;
[0110] (2) Gastrodin incubation group: 40 μL of gastrodin (500 μg / mL), 20 μL of HLM and 100 μL of PBS were mixed, pre-incubated for 5 min, and 20 μL of NADPH was added. Incubation continued for 45 min, and 600 μL of ice methanol was added;
[0111] (3) Chrysophanol and gastrodin control group: 40 μL gastrodin (500 μg / mL), 40 μL chrysophanol (500 μg / mL), 20 μL HLM and 80 μL PBS were mixed, pre-incubated for 5 min, and 20 μL PBS was added. Incubation continued for 45 min, and 600 μL ice methanol was added;
[0112] (4) Chrysophanol and gastrodin combined incubation group: 40 μL gastrodin (500 μg / mL), 40 μL chrysophanol (500 μg / mL), 20 μL HLM and 80 μL PBS were mixed and pre-incubated for 5 min. 20 μL NADPH was added. Incubation continued for 45 min, and 600 μL ice methanol was added.
[0113] 1.3 P450 enzyme incubation scheme of gastrodin and chrysophanol
[0114] The total volume of the incubation system was 200 μL, and the system contained 40 μL of drug, 20 μL of CYP1A2 enzyme (protein concentration 1.0 mg / mL), 40 μL of NADPH, and 100 μL of phosphate buffer (PBS, 0.1 M, pH=7.4).
[0115] The experimental steps are as follows: CYP1A2 enzyme is mixed with the drug, pre-incubated at 37°C for 5 minutes, NADPH is added to start the reaction, and the reaction is continued at 37°C for 45 minutes. The experiment uses 500μg / mL of chrysophanol and 500μg / mL of gastrodin to study the changes in the metabolic rate of chrysophanol after the combination of chrysophanol and gastrodin. The experimental groups are as follows:
[0116] (1) Gastrodin control group: 40 μL of gastrodin, 20 μL of CYP1A2 and 100 μL of PBS were mixed, pre-incubated for 5 min, and 20 μL of PBS was added. Incubation was continued for 45 min, and 600 μL of ice methanol was added;
[0117] (2) Gastrodin incubation group: 40 μL of gastrodin, 20 μL of CYP1A2 and 100 μL of PBS were mixed, pre-incubated for 5 min, and 20 μL of NADPH was added. Incubation continued for 45 min, and 600 μL of ice methanol was added;
[0118] (3) Chrysophanol and gastrodin control group: 40 μL gastrodin, 40 μL chrysophanol, 20 μL CYP1A2 and 80 μL PBS were mixed, pre-incubated for 5 min, and 20 μL PBS was added. Incubation continued for 45 min, and 600 μL ice methanol was added;
[0119] (4) Chrysophanol and gastrodin combined incubation group: 40 μL gastrodin, 40 μL chrysophanol, 20 μL CYP1A2 and 80 μL PBS were mixed and pre-incubated for 5 min. 20 μL NADPH was added. Incubation continued for 45 min, and 600 μL ice methanol was added.
[0120] 1.4 Human liver microsome incubation protocol for hesperidin and chrysophanol
[0121] Referring to the incubation scheme under 1.3 of this example, 500 μg / mL chrysophanol and 500 μg / mL hesperidin were combined to conduct group experiments to study the changes in the metabolic rate of chrysophanol after the combination of chrysophanol and hesperidin.
[0122] The experimental groups are as follows:
[0123] (1) Hesperidin control group: 40 μL hesperidin, 20 μL HLM and 100 μL PBS were mixed, pre-incubated for 5 min, and 20 μL PBS was added. Incubation continued for 45 min, and 600 μL ice methanol was added;
[0124] (2) Hesperidin incubation group: 40 μL hesperidin, 20 μL HLM and 100 μL PBS were mixed, pre-incubated for 5 min, and 20 μL NADPH was added. Incubation continued for 45 min, and 600 μL ice methanol was added;
[0125] (3) Chrysophanol and hesperidin combination control group: 40 μL hesperidin, 40 μL chrysophanol, 20 μL HLM and 80 μL PBS were mixed, pre-incubated for 5 min, and 20 μL PBS was added. Incubation continued for 45 min, and 600 μL ice methanol was added;
[0126] (4) Chrysophanol and hesperidin combined incubation group: 40 μL hesperidin, 40 μL chrysophanol, 20 μL HLM and 80 μL PBS were mixed and pre-incubated for 5 min. 20 μL NADPH was added. Incubation continued for 45 min, and 600 μL ice methanol was added.
[0127] 2. Experimental results
[0128] 2.1 Screening results of key metabolic enzymes of chrysophanol
[0129] The six enzymes were incubated with chrysophanol, and the results showed that the peak area of chrysophanol in the CYP1A2 enzyme incubation group was 22439, which was 7005 less than that in the control group. The calculated metabolic rate was 31.25% (specifically Figure 7 The mass spectrometry results showed that the mass-to-charge ratio of the metabolite was 269.04Da and the retention time was 10.88min. No metabolites of chrysophanol were found in the other five recombinant P450 metabolomes (see Figure 8 The results showed that CYP1A2 was the main metabolic enzyme of chrysophanol in the liver.
[0130] 2.2 Gastrodin promotes the metabolism of chrysophanol in liver microsomes
[0131] According to the calculation formula of chrysophanol metabolism rate, the metabolic rate of chrysophanol in human liver microsomes is 43.41% (specifically, Fig. 9 The metabolic rate of chrysophanol after gastrodin was 68.61% (as shown in the table below). Fig.10 Compared with the chrysophanol group, it increased by 18.40%. The data showed that gastrodin can effectively promote the metabolism of chrysophanol in human liver microsomes.
[0132] 2.3 Gastrodin promotes the metabolism of chrysophanol by CYP1A2
[0133] According to the calculation formula of chrysophanol metabolism rate, the metabolic rate of chrysophanol by CYP1A2 was 32.31% (specifically, Fig.11 The metabolic rate of chrysophanol in the combination group was 47.25% (as shown in Fig.12 Compared with the chrysophanol group, it increased by 14.91%. The data showed that gastrodin can effectively promote the metabolism of chrysophanol by CYP1A2.
[0134] 2.4 Hesperidin inhibits the metabolism of chrysophanol in human liver microsomes
[0135] According to the calculation formula of chrysophanol metabolism rate, the metabolic rate of chrysophanol in human liver microsomes is 42.48% (specifically, Fig.13 The metabolic rate of chrysophanol in the combination group was 13.29% (as shown in Fig.14 Compared with the chrysophanol group, it was reduced by 29.19%. The data showed that hesperidin can inhibit the metabolism of chrysophanol in human liver microsomes.
[0136] In summary, in order to explore the specific metabolic mechanism of chrysophanol, this example co-incubated 6 P450 recombinant enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4) with chrysophanol. The results showed that in human liver microsomes, CYP1A2 enzyme was the main metabolic enzyme of chrysophanol, and its metabolic rate was 31.25%. After metabolism, M1-type hydroxylated metabolites: aloe-emodin can be generated. It was revealed that the main metabolic mechanism of chrysophanol is related to the hydroxylation reaction of CYP1A2. The results showed that gastrodin promoted the metabolism of chrysophanol by human liver microsomes and CYP1A2 enzymes, and hesperidin inhibited the metabolism of chrysophanol by human liver microsomes.
[0137] Example 3 Effect of Gastrodin and Chrysophanol on Liver Cell Activity
[0138] 1. Experimental Methods
[0139] 1.1 Normal hepatocyte culture
[0140] (1) Cell recovery
[0141] ① Open the constant temperature water bath in advance and set the temperature to 37°C;
[0142] ② When the constant temperature water bath reaches the preset temperature and maintains for 5 minutes, put DMEM high-glucose culture medium, penicillin-streptomycin double antibody solution, FBS and trypsin into the water bath for preheating;
[0143] ③Ultraviolet sterilization clean bench for 30 minutes, turn on ventilation and lighting systems, and spray 75% alcohol for disinfection;
[0144] ④ Pipette 5mL of 1% penicillin-streptomycin dual antibody solution and add it to DMEM and mix well. Pipette 45mL of the mixture and 5mL of 10% FBS in a 50mL centrifuge tube and mix well to prepare complete culture medium. Pipette 8-10mL of complete culture medium into a clean 10cm cell culture dish for later use;
[0145] ⑤ Take out the cryopreserved tube containing LO2 cells and shake it quickly in a water bath to thaw it within 1 to 2 minutes. Disinfect it with 75% alcohol and place it vertically in a biosafety cabinet. Use a pipette to transfer the cells in the cryopreserved tube to a 15mL sterile centrifuge tube and mix it with complete culture medium in a ratio of 1:2;
[0146] ⑥ Place the test tube in a low-speed centrifuge, centrifuge at room temperature, 720 rpm for 5 minutes;
[0147] ⑦Discard the supernatant and add 3 mL of DMEM high-glucose medium (containing 10% FBS + 1% penicillin-streptomycin) to resuspend the cells;
[0148] ⑧ Use a pipette to transfer the cell suspension to a 10 cm cell culture dish that has been pre-added with complete culture medium. Shake to mix well and place in a 37°C cell culture incubator for culture.
[0149] (2) Cell passaging and plating
[0150] ①Change medium or subculture according to cell growth rate and growth status;
[0151] ② When the cell growth density reaches 80% or above, cell subculture is performed;
[0152] ③Discard the original culture medium and wash thoroughly with PBS for 3 times;
[0153] ④ Add trypsin to digest the adherent cells, place them in a 37°C incubator, and observe the cell digestion under a microscope after 2 minutes;
[0154] ⑤ When the cells are round, aspirate the trypsin to end the digestion. Add 3 mL of complete culture medium, pipette and collect the cell suspension into a 15 mL centrifuge tube;
[0155] ⑥ Place the centrifuge tube in a centrifuge, centrifuge at room temperature, 720 rpm for 5 minutes;
[0156] ⑦Discard the supernatant and add 3mL complete culture medium to resuspend the cells. Use a pipette to aspirate the cell suspension and transfer it to a new cell culture dish. Shake well and place in a cell culture incubator for further culture.
[0157] (3) Cell cryopreservation
[0158] ① Repeat the above “cell passaging and plating” steps until the centrifugation is completed;
[0159] ②Discard the supernatant, add the prepared cryopreservation solution containing 8% fetal bovine serum to resuspend the cells, and dispense into the labeled cell cryopreservation tubes at 1 mL / tube; ③Store the cell cryopreservation tubes in a gradient cooling box, immediately place them in a -80℃ refrigerator for 24 hours, and then transfer the cell cryopreservation tubes to a liquid nitrogen tank for long-term storage. After 2-3 months, randomly revive a tube of cells from the same batch to observe whether the cells are in good condition.
[0160] 1.2 Hepatocyte morphology observation experiment
[0161] LO2 cells in the logarithmic growth phase were inoculated into 6-well plates and cultured in a cell culture incubator at 37°C, 5% CO2 and saturated humidity. When the cell proliferation reached 80%, chrysophanol and gastrodin solutions were added respectively and cultured for 24 hours. The morphology and growth of the cells were observed and photographed using an inverted microscope. The experimental groups were as follows:
[0162] ①LO2 cells + serum-free DMEM culture medium;
[0163] ②40 μg / mL chrysophanol + LO2 cells + serum-free DMEM culture medium;
[0164] ③1600 μg / mL gastrodin + LO2 cells + serum-free DMEM culture medium;
[0165] ④40μg / mL chrysophanol + 400μg / mL gastrodin + LO2 cells + serum-free DMEM culture medium;
[0166] ⑤40μg / mL chrysophanol + 800μg / mL gastrodin + LO2 cells + serum-free DMEM culture medium;
[0167] ⑥40μg / mL chrysophanol + 1600μg / mL gastrodin + LO2 cells + serum-free DMEM culture medium.
[0168] 1.3 Cell viability assay
[0169] (1) Solution preparation
[0170] Preparation of chrysophanol solution: accurately weigh 1 mg of chrysophanol standard, dissolve it in 1 mL of methanol, ultrasonically dissolve it for 5 minutes, and prepare a standard stock solution with a concentration of 1 mg / mL. Use DMEM high-glucose culture medium containing 5% fetal bovine serum to dilute the stock solution into chrysophanol solutions with concentrations of 1 μg / mL, 5 μg / mL, 10 μg / mL, 20 μg / mL, 25 μg / mL, 40 μg / mL and 80 μg / mL for later use. The content of organic solvent is less than 1%.
[0171] Preparation of gastrodin solution: accurately weigh 5 mg of gastrodin standard, dissolve it in 1 mL of PBS, and prepare a standard stock solution with a mass concentration of 5 mg / mL. Use DMEM high-glucose medium containing 5% fetal bovine serum to dilute the stock solution into gastrodin solutions with concentrations of 100 μg / mL, 200 μg / mL, 400 μg / mL, 800 μg / mL, 1600 μg / mL, 2000 μg / mL, and 3200 μg / mL for later use.
[0172] (2) CCK-8 experimental protocol
[0173] Discard the supernatant, add 3 mL of pre-warmed DMEM high-glucose medium (containing 10% FBS + 1% penicillin-streptomycin), and pipette to collect the cells into a 15 mL centrifuge tube. After counting the cells, adjust the concentration of the cell suspension to 8 × 10 5cells / mL. Inoculate in 3 96-well plates, 100 μL per well, and set up 6 parallel wells in each group. Culture at 37℃ for 24 hours to allow cells to adhere. Add chrysophanol and gastrodin solution, and set up a blank group without cells and a control group without drug. After the drug culture is completed, discard the treatment solution and add 10% CCK-8 solution to each sample well. Use an enzyme reader to detect the absorbance at a wavelength of 450nm. The experimental groups are as follows:
[0174] Experimental grouping of chrysophanol's effect on LO2 cell activity
[0175] ① (1, 5, 10, 20, 25, 40, 80 μg / mL) chrysophanol + cells + serum-free DMEM culture medium (24 h);
[0176] ② (1, 5, 10, 20, 25 μg / mL) chrysophanol + cells + serum-free DMEM culture medium (24 h);
[0177] ③ (1, 5, 10, 20, 25 μg / mL) chrysophanol + cells + serum-free DMEM culture medium (48 h);
[0178] ④ (1, 5, 10, 20, 25 μg / mL) Chrysophanol + cells + serum-free DMEM culture medium (72 h). LO2 cells were inoculated in a 10 cm cell culture dish, and a control group without drug and a blank group without cells were set up.
[0179] Experimental grouping of the effect of chrysophanol combined with gastrodin on the activity of LO2 cells
[0180] ①80 μg / mL chrysophanol + (100, 200, 400, 800, 1600, 3200 μg / mL) gastrodin + LO2 cells + serum-free DMEM culture medium (24 h);
[0181] ②80 μg / mL chrysophanol + (100, 200, 400, 800, 1600, 2000, 3200 μg / mL) gastrodin + LO2 cells + serum-free DMEM culture medium (24 h);
[0182] ③80 μg / mL chrysophanol + (100, 200, 400, 800, 1600, 2000, 3200 μg / mL) gastrodin + LO2 cells + serum-free DMEM culture medium (48 h);
[0183] ④80μg / mL chrysophanol + (100, 200, 400, 800, 1600, 2000, 3200μg / mL) gastrodin + LO2 cells + serum-free DMEM culture medium (72h).
[0184] LO2 cells in the logarithmic growth phase were inoculated into a cell culture dish with a diameter of 10 cm and cultured with DMEM high-glucose medium (containing 10% FBS + 1% penicillin-streptomycin). A control group without drug addition and a blank group without cells were set up on each plate.
[0185] 1.4 Flow cytometry and immunoblotting were used to analyze the effects of gastrodin combined with chrysophanol on hepatocyte activity.
[0186] 2. Experimental conclusion
[0187] 2.1 Effects of chrysophanol combined with gastrodin on the activity of normal human liver cells
[0188] 2.1.1 Effects of Chrysophanol on the Activity of Normal Human Hepatocytes
[0189] In order to study the effect of chrysophanol on the activity of normal human liver cells, this experiment used CCK-8 method to detect cell viability. The experimental results showed that chrysophanol inhibited the activity of LO2 cells in a concentration-dependent manner (specifically, Fig.15 As shown). According to the above experimental results, a concentration gradient of 0-25 μg / mL chrysophanol was screened to study the effect of time on cell viability. Three time points of 24h, 48h and 72h were set. The results showed that with the increase of time, the inhibition rate of LO2 cells by the same concentration of chrysophanol solution increased, indicating that the inhibition of LO2 cell viability by chrysophanol was time-dependent.
[0190] 2.1.2 Effects of chrysophanol and gastrodin on hepatocyte activity
[0191] Gastrodin had little effect on the viability of LO2 cells (specifically Fig.16 As shown). In addition, this example also studies the effect of the combination of chrysophanol and gastrodin on the viability of LO2 cells. According to the results of the LO2 cell viability test of chrysophanol, chrysophanol concentrations (25 μg / mL and 80 μg / mL) with significant inhibitory effects were selected for combination with gradient concentrations of gastrodin solutions (100, 200, 400, 800, 1600, 2000 and 3200 μg / mL). The results show that gastrodin can reduce the cytotoxicity of chrysophanol to LO2 cells in a concentration-dependent manner.
[0192] 2.2 Effects of chrysophanol and gastrodin on hepatocyte morphology
[0193] After 24 hours of chrysophanol treatment, the cells in the negative control group were flat, polygonal, closely spaced, and pebble-like, with good cell growth and a clear background. In the 1600μg / mL gastrodin group, there was no obvious change in cell morphology. In the 40μg / mL chrysophanol group, the cells became round, shrank in size, and the cytoplasm shrank. Most of the cells were uneven in morphology, floating in the culture medium, and died and collapsed. Compared with the chrysophanol group, the high-concentration gastrodin group significantly increased the number of cells attached to the wall, and the cells were closely arranged, connected to each other, and in good condition (for example, Fig.17 shown).
[0194] 2.3 Effects of chrysophanol combined with gastrodin on apoptosis and cell cycle of normal human liver cells
[0195] After 24 hours of treatment with chrysophanol, the apoptosis rate of LO2 cells increased significantly (p<0.001) by 54.73% compared with the control group without drug addition (see Fig.18 As shown). After being combined with gastrodin, the cell apoptosis rate decreased in a concentration-dependent manner. Compared with the chrysophanol group, the cell apoptosis rate in the 400μg / mL gastrodin group decreased by 12.60% (p<0.05), and the 800μg / mL gastrodin group decreased by 32.36% (p<0.001). As the concentration of gastrodin increased, the apoptosis rate decreased. The results showed that gastrodin can significantly reduce the apoptosis of LO2 cells caused by chrysophanol, and it is dose-dependent. Compared with the control group, the chrysophanol-treated group blocked the S-G2 phase of the cells (p<0.001) (specifically as shown). Fig.19 As shown in Figure 2 ). After being combined with gastrodin, the S-G2 phase of LO2 cells was prolonged with the increase of gastrodin concentration. The 400μg / mL gastrodin group increased by 8.33%, and the 800μg / mL gastrodin group increased by 9.26%, which was concentration-dependent. The effects of gastrodin and chrysophanol on apoptosis and cell cycle of LO2 cells before and after combination are shown in Figure 2 Fig. 20 shown.
[0196] 2.4 Effects of chrysophanol combined with gastrodin on the expression of apoptosis-related proteins in normal human cells
[0197] BCL2associatedX (BAX) is a pro-apoptotic protein. Compared with the normal group, the expression of BAX protein in the 40μg / mL chrysophanol group was significantly upregulated (p<0.05), and the protein content increased by 28.81%, leading to cell apoptosis. Compared with the chrysophanol group, the BAX protein content in the 200μg / mL gastrodin group decreased by 14.48% (p<0.05), the 800μg / mL gastrodin group decreased by 53.38% (p<0.05), and the 1600μg / mL gastrodin group decreased by 58.43% (p<0.01). This suggests that gastrodin can reduce cell apoptosis by downregulating the expression of BAX. Among them, the effects of chrysophanol combined with gastrodin on apoptosis-related proteins are as follows: Fig.21shown.
[0198] Overexpression of cysteineaspartate-specific protease (Caspase-3) can lead to cell apoptosis. Chrysophanol upregulated the expression of this protein. Compared with the control group, the protein content of Caspase-3 increased by 53.89% (p<0.01). Gastrodin reduced the apoptosis of LO2 cells by downregulating this protein. Compared with the chrysophanol group, the protein content of Caspase-3 in the 200μg / mL gastrodin group decreased by 12.82% (p<0.05), the 800μg / mL gastrodin group decreased by 57.21% (p<0.01), and the 1600μg / mL gastrodin group decreased by 94.48% (p<0.001), showing a concentration-dependent manner.
[0199] In summary, the cytotoxicity of chrysophanol is related to proteins Bax and Caspase-3, and gastrodin can reduce the cytotoxicity of chrysophanol by inhibiting the expression of these two proteins. After chrysophanol was combined with gastrodin, the S and G2 phases of LO2 cells were prolonged, thereby improving cell apoptosis, indicating that gastrodin can improve the cell cycle arrest caused by chrysophanol.
[0200] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the purpose and scope of the technical solution of the present invention, which should be covered by the scope of the claims of the present invention.
Claims
1. A method for reducing the toxicity of chrysophanol, It is characterized in that The method comprises combining chrysophanol with gastrodin.
2. The method according to claim 1, It is characterized in that The concentration ratio of chrysophanol to gastrodin is 1:1-1:
40.
3. A drug capable of reducing the toxicity of chrysophanol, It is characterized in that The drug includes gastrodin.
4. Application of gastrodin in the preparation of drugs for reducing the toxicity of chrysophanol, It is characterized in that The method of reducing the toxicity of chrysophanol includes promoting the metabolism of chrysophanol by human liver microsomes and reducing the influence of chrysophanol on the activity of liver cells.
5. The use according to claim 4, It is characterized in that The method for reducing the effect of chrysophanol on the activity of liver cells includes inhibiting the effect of chrysophanol on the morphology of liver cells, reducing the apoptosis of liver cells caused by chrysophanol, regulating the cycle of liver cells and regulating the expression of proteins related to apoptosis of normal human cells.
6. The use according to claim 4, It is characterized in that The regulation of the expression of proteins related to apoptosis of normal human cells includes down-regulating the expression of proteins Bax and Caspase-3 caused by chrysophanol.
7. The use according to claim 4, It is characterized in that The regulating the liver cell cycle includes prolonging the S and G2 phases of the liver cells.
